Sign in
MRTX Stock Price, Chart, Stats & News
Mirati Therapeutics, Inc.
Save
4.12B
Market cap
–
Current P/E
–
Forward P/E
MRTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 95.18% |
Operating margin | -6107.98% |
Pretax margin | -5953.35% |
Net margin | -5957.44% |
Effective tax rate | -0.07% |
ROA | -61.60% |
ROE | -61.91% |
D/E | 0.05x |
Interest coverage ratio | – |
MRTX valuation
P/E | – |
P/S | 331.11x |
P/B | 3.31x |
P/CF | -5.79x |
P/FCF | -7.16x |
P/OCF | -5.79x |
PEG | -0.04x |
EV multiple | -5.68x |
About
Mirati Therapeutics, Inc. is a U. S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers.
Similar securities
Based on sector and market capitalization
Report issue